Bristol Myers Squibb Provides Update On First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia For Crohn's Disease; Study Did Not Meet Its Primary Endpoint Of Clinical Remission At Week 12

Bristol-Myers Squibb Company -0.52%

Bristol-Myers Squibb Company

BMY

48.26

-0.52%

The safety profile of Zeposia in this study was consistent with that observed in previously reported trials. The company will complete a full evaluation of the YELLOWSTONE trial data and work with investigators to share the results with the scientific community in the future.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via